Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for MDGL

Stock Name	Madrigal Pharmaceuticals Inc
Ticker	MDGL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5588681057
LEI	549300CHIMT2EUSNJB60

Show aggregate MDGL holdings

News associated with MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $483.38 Consensus Target Price from Brokerages: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target […] - 2025-09-17 02:42:46
Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) and BioNxt Solutions (OTCMKTS:BNXTF): Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Madrigal Pharmaceuticals and BioNxt […] - 2025-08-28 04:46:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-08-20 03:12:44
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Insider Selling: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $369.84, but opened at $354.56. Madrigal Pharmaceuticals shares last traded at $364.21, with a volume of 83,865 shares changing hands. Specifically, General Counsel Shannon T. Kelley sold […] - 2025-08-20 02:17:00
Stocks Mixed Before Trump-Zelenskiy Meeting and Retailer Earnings: The S&P 500 Index ($SPX ) (SPY ) today is down by -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.09%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September... - 2025-08-18 14:26:35
Stocks Slightly Lower on Concern Over Progress to End Russian-Ukrainian War: The S&P 500 Index ($SPX ) (SPY ) today is down by -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.17%. September E-mini S&P futures (ESU25 ) are down -0.06%, and September... - 2025-08-18 12:43:44
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $3,652,000.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Kenneth Bate sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $365.20, for a total transaction of $3,652,000.00. Following the transaction, the director owned 2,627 shares of the company’s stock, […] - 2025-08-18 05:18:50
Cetera Investment Advisers Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Cetera Investment Advisers reduced its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 1.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,832 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Cetera Investment Advisers’ holdings in Madrigal Pharmaceuticals were worth $938,000 as of its […] - 2025-08-13 04:49:04
1,003 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Blair William & Co. IL: Blair William & Co. IL bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,003 shares of the biopharmaceutical company’s stock, valued at approximately $332,000. Other hedge funds also […] - 2025-08-12 05:00:47
Zurcher Kantonalbank Zurich Cantonalbank Sells 291 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Zurcher Kantonalbank Zurich Cantonalbank trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 12.0% during the first quarter, HoldingsChannel reports. The firm owned 2,138 shares of the biopharmaceutical company’s stock after selling 291 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Madrigal Pharmaceuticals were worth $708,000 as of […] - 2025-08-07 04:26:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up on Strong Earnings: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $312.11, but opened at $350.00. Madrigal Pharmaceuticals shares last traded at $330.70, with a volume of 156,412 shares traded. The biopharmaceutical company reported ($1.90) […] - 2025-08-07 02:12:57
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 1,000 Shares of Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Rebecca Taub sold 1,000 shares of the company’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $350.00, for a total transaction of $350,000.00. Following the transaction, the director owned 461,044 shares in the company, valued at $161,365,400. […] - 2025-07-24 05:51:01
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $490,042.00 in Stock: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 1,400 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.03, for a total value of $490,042.00. Following the completion of the sale, the director directly owned 187,164 […] - 2025-07-24 05:50:51
New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): New York State Common Retirement Fund lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,771 shares of the biopharmaceutical company’s stock after acquiring an additional 3,956 […] - 2025-07-18 06:22:45
Mutual of America Capital Management LLC Boosts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Mutual of America Capital Management LLC grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,263 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during […] - 2025-07-18 05:49:00
D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): D.A. Davidson & CO. grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 203.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 2,173 shares of the biopharmaceutical company’s stock after acquiring an additional 1,458 shares during the period. D.A. Davidson & CO.’s […] - 2025-07-10 05:25:03
First Horizon Advisors Inc. Grows Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): First Horizon Advisors Inc. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 38.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 157 shares of the biopharmaceutical company’s stock after purchasing an additional 44 shares during the period. First Horizon Advisors Inc.’s […] - 2025-07-08 05:08:55
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $420.63 Consensus Price Target from Analysts: Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The […] - 2025-07-04 02:40:48
QRG Capital Management Inc. Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): QRG Capital Management Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 726 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. Other institutional investors also recently bought and sold shares of the company. […] - 2025-06-24 04:42:49
Head-To-Head Analysis: Madrigal Pharmaceuticals (NASDAQ:MDGL) and Larimar Therapeutics (NASDAQ:LRMR): Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Profitability This table compares Larimar Therapeutics and Madrigal […] - 2025-06-12 03:09:35
Wellington Management Group LLP Has $2.52 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Wellington Management Group LLP lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,172 shares of the biopharmaceutical company’s stock after selling 859 shares during the period. Wellington Management Group LLP’s holdings […] - 2025-06-06 05:04:52
Analysts Anticipate 12% Upside For The Holdings of AVLC: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:37:18
Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) and Adicet Bio (NASDAQ:ACET): Adicet Bio (NASDAQ:ACET – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Volatility & Risk Adicet Bio has a beta […] - 2025-05-21 03:01:02
MDGL Crosses Below Key Moving Average Level: In trading on Wednesday, shares of Madrigal Pharmaceuticals Inc (Symbol: MDGL) crossed below their 200 day moving average of $292.11, changing hands as low as $287.01 per share. Madrigal Pharmaceuticals Inc shares are currently trading down about 2.5% on the day. The chart bel - 2025-05-14 12:56:35
Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 06:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00: Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 04:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC: Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 05:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 05:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC: Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 05:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 04:20:54

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc MDGL holdings

Date	Number of MDGL Shares Held	Base Market Value of MDGL Shares	Local Market Value of MDGL Shares	Change in MDGL Shares Held	Change in MDGL Base Value	Current Price per MDGL Share Held	Previous Price per MDGL Share Held
2025-11-12 (Wednesday)	2,939	USD 1,554,555	USD 1,554,555	-9	USD -41,787	USD 528.94	USD 541.5
2025-11-11 (Tuesday)	2,948	USD 1,596,342	USD 1,596,342	0	USD 134,488	USD 541.5	USD 495.88
2025-11-10 (Monday)	2,948	USD 1,461,854	USD 1,461,854	0	USD 19,516	USD 495.88	USD 489.26
2025-11-07 (Friday)	2,948	USD 1,442,338	USD 1,442,338	0	USD 2,004	USD 489.26	USD 488.58
2025-11-06 (Thursday)	2,948	USD 1,440,334	USD 1,440,334	-9	USD 33,186	USD 488.58	USD 475.87
2025-11-05 (Wednesday)	2,957	USD 1,407,148	USD 1,407,148	-90	USD 52,330	USD 475.87	USD 444.64
2025-11-04 (Tuesday)	3,047	USD 1,354,818	USD 1,354,818	-18	USD 90,965	USD 444.64	USD 412.35
2025-11-03 (Monday)	3,065	USD 1,263,853	USD 1,263,853	-18	USD -27,616	USD 412.35	USD 418.9
2025-10-31 (Friday)	3,083	USD 1,291,469	USD 1,291,469	0	USD -26,575	USD 418.9	USD 427.52
2025-10-30 (Thursday)	3,083	USD 1,318,044	USD 1,318,044	0	USD 18,251	USD 427.52	USD 421.6
2025-10-29 (Wednesday)	3,083	USD 1,299,793	USD 1,299,793	0	USD -23,369	USD 421.6	USD 429.18
2025-10-28 (Tuesday)	3,083	USD 1,323,162	USD 1,323,162	27	USD -8,582	USD 429.18	USD 435.78
2025-10-27 (Monday)	3,056	USD 1,331,744	USD 1,331,744	0	USD 43,640	USD 435.78	USD 421.5

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MDGL by Blackrock for IE00B3VWM098

Show aggregate share trades of MDGL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 SELL -9 542.190 520.000 522.219 USD -4,700 329.60 Loss of -1,734 on sale
2025-11-06 SELL -9 491.910 471.220 473.289 USD -4,260 325.97 Loss of -1,326 on sale
2025-11-05 SELL -90 496.980 446.200 451.278 USD -40,615 325.18 Loss of -11,349 on sale
2025-11-04 SELL -18 469.950 405.000 411.495 USD -7,407 324.55 Loss of -1,565 on sale
2025-11-03 SELL -18 421.640 399.000 401.264 USD -7,223 324.09 Loss of -1,389 on sale
2025-10-28 BUY 27 429.180 435.000 434.418 USD 11,729 321.92
2025-10-24 SELL -9 421.500 429.980 429.132 USD -3,862 320.76 Loss of -975 on sale
2025-10-15 BUY 54 433.450 451.410 449.614 USD 24,279 316.33
2025-10-02 BUY 9 449.640 462.880 461.556 USD 4,154 314.84
2025-09-30 BUY 18 458.660 460.220 460.064 USD 8,281 313.22
2025-08-21 SELL -7 407.090 414.500 413.759 USD -2,896 309.93 Loss of -727 on sale
2025-07-31 BUY 21 302.510 312.050 311.096 USD 6,533 309.48
2025-06-30 SELL -14 302.640 308.920 308.292 USD -4,316 309.52 Profit of 17 on sale
2025-06-25 SELL -7 277.640 284.990 284.255 USD -1,990 309.88 Profit of 179 on sale
2025-06-20 SELL -14 285.730 287.850 287.638 USD -4,027 310.42 Profit of 319 on sale
2025-05-30 BUY 682 275.260 279.150 278.761 USD 190,115 313.72
2025-05-23 BUY 5 267.560 274.840 274.112 USD 1,371 315.56
2025-05-19 SELL -5 290.720 292.480 292.304 USD -1,462 316.67 Profit of 122 on sale
2025-05-15 SELL -15 291.820 291.970 291.955 USD -4,379 317.11 Profit of 377 on sale
2025-05-12 SELL -5 300.760 307.540 306.862 USD -1,534 317.76 Profit of 55 on sale
2025-05-09 SELL -5 294.640 307.490 306.205 USD -1,531 317.97 Profit of 59 on sale
2025-04-30 SELL -5 333.910 345.730 344.548 USD -1,723 318.45 Loss of -131 on sale
2025-04-24 SELL -10 319.930 320.920 320.821 USD -3,208 317.99 Loss of -28 on sale
2025-04-17 SELL -5 301.660 306.810 306.295 USD -1,531 318.84 Profit of 63 on sale
2025-04-15 SELL -15 321.100 330.640 329.686 USD -4,945 318.94 Loss of -161 on sale
2025-04-14 SELL -15 322.320 327.850 327.297 USD -4,909 318.90 Loss of -126 on sale
2025-04-09 SELL -20 313.950 333.320 331.383 USD -6,628 319.11 Loss of -245 on sale
2025-04-07 SELL -35 310.520 321.590 320.483 USD -11,217 319.40 Loss of -38 on sale
2025-04-04 SELL -50 314.390 325.080 324.011 USD -16,201 319.46 Loss of -228 on sale
2025-03-31 BUY 5 331.230 333.000 332.823 USD 1,664 319.08
2025-03-19 SELL -10 340.770 341.180 341.139 USD -3,411 317.00 Loss of -241 on sale
2025-03-14 SELL -30 348.350 348.350 348.350 USD -10,451 315.90 Loss of -974 on sale
2025-03-13 SELL -10 323.020 332.400 331.462 USD -3,315 315.80 Loss of -157 on sale
2025-03-12 SELL -170 327.310 344.170 342.484 USD -58,222 315.63 Loss of -4,565 on sale
2025-03-07 SELL -10 331.410 339.080 338.313 USD -3,383 314.89 Loss of -234 on sale
2025-03-06 SELL -15 328.770 350.000 347.877 USD -5,218 314.67 Loss of -498 on sale
2025-03-03 SELL -5 313.470 335.400 333.207 USD -1,666 314.06 Loss of -96 on sale
2025-02-28 BUY 337 341.270 342.270 342.170 USD 115,311 313.61
2025-02-26 SELL -4 355.880 377.460 375.302 USD -1,501 312.52 Loss of -251 on sale
2025-02-25 SELL -12 309.490 320.540 319.435 USD -3,833 312.57 Loss of -82 on sale
2025-02-18 BUY 20 339.870 341.020 340.905 USD 6,818 310.12
2025-02-13 BUY 4 351.710 352.990 352.862 USD 1,411 308.21
2025-02-12 BUY 4 340.170 340.180 340.179 USD 1,361 307.55
2025-02-11 BUY 12 331.790 336.710 336.218 USD 4,035 307.05
2025-02-06 BUY 36 330.270 349.280 347.379 USD 12,506 305.28
2025-01-27 BUY 4 310.920 314.590 314.223 USD 1,257 300.31
2024-12-30 BUY 20 311.620 315.270 314.905 USD 6,298 297.51
2024-12-06 BUY 16 320.840 321.990 321.875 USD 5,150 295.53
2024-12-05 BUY 4 313.050 321.140 320.331 USD 1,281 294.93
2024-12-04 BUY 20 318.480 328.170 327.201 USD 6,544 294.08
2024-11-29 BUY 20 328.190 331.150 330.854 USD 6,617 290.65
2024-11-27 BUY 16 331.450 336.450 335.950 USD 5,375 287.10
2024-11-26 BUY 4 336.740 347.060 346.028 USD 1,384 284.85
2024-11-21 BUY 20 329.240 329.930 329.861 USD 6,597 276.04
2024-11-20 BUY 12 317.090 323.990 323.300 USD 3,880 273.76
2024-11-18 BUY 48 303.490 308.430 307.936 USD 14,781 269.37
2024-11-12 BUY 32 339.040 341.190 340.975 USD 10,911 264.73
2024-11-08 BUY 20 350.700 357.050 356.415 USD 7,128 258.59
2024-11-07 BUY 60 354.850 368.290 366.946 USD 22,017 251.19
2024-11-06 BUY 8 338.220 345.040 344.358 USD 2,755 243.93
2024-10-31 BUY 4 259.340 263.540 263.120 USD 1,052 209.92
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	SELL	-9	542.190	520.000	522.219	USD -4,700	329.60 Loss of -1,734 on sale
2025-11-06	SELL	-9	491.910	471.220	473.289	USD -4,260	325.97 Loss of -1,326 on sale
2025-11-05	SELL	-90	496.980	446.200	451.278	USD -40,615	325.18 Loss of -11,349 on sale
2025-11-04	SELL	-18	469.950	405.000	411.495	USD -7,407	324.55 Loss of -1,565 on sale
2025-11-03	SELL	-18	421.640	399.000	401.264	USD -7,223	324.09 Loss of -1,389 on sale
2025-10-28	BUY	27	429.180	435.000	434.418	USD 11,729	321.92
2025-10-24	SELL	-9	421.500	429.980	429.132	USD -3,862	320.76 Loss of -975 on sale
2025-10-15	BUY	54	433.450	451.410	449.614	USD 24,279	316.33
2025-10-02	BUY	9	449.640	462.880	461.556	USD 4,154	314.84
2025-09-30	BUY	18	458.660	460.220	460.064	USD 8,281	313.22
2025-08-21	SELL	-7	407.090	414.500	413.759	USD -2,896	309.93 Loss of -727 on sale
2025-07-31	BUY	21	302.510	312.050	311.096	USD 6,533	309.48
2025-06-30	SELL	-14	302.640	308.920	308.292	USD -4,316	309.52 Profit of 17 on sale
2025-06-25	SELL	-7	277.640	284.990	284.255	USD -1,990	309.88 Profit of 179 on sale
2025-06-20	SELL	-14	285.730	287.850	287.638	USD -4,027	310.42 Profit of 319 on sale
2025-05-30	BUY	682	275.260	279.150	278.761	USD 190,115	313.72
2025-05-23	BUY	5	267.560	274.840	274.112	USD 1,371	315.56
2025-05-19	SELL	-5	290.720	292.480	292.304	USD -1,462	316.67 Profit of 122 on sale
2025-05-15	SELL	-15	291.820	291.970	291.955	USD -4,379	317.11 Profit of 377 on sale
2025-05-12	SELL	-5	300.760	307.540	306.862	USD -1,534	317.76 Profit of 55 on sale
2025-05-09	SELL	-5	294.640	307.490	306.205	USD -1,531	317.97 Profit of 59 on sale
2025-04-30	SELL	-5	333.910	345.730	344.548	USD -1,723	318.45 Loss of -131 on sale
2025-04-24	SELL	-10	319.930	320.920	320.821	USD -3,208	317.99 Loss of -28 on sale
2025-04-17	SELL	-5	301.660	306.810	306.295	USD -1,531	318.84 Profit of 63 on sale
2025-04-15	SELL	-15	321.100	330.640	329.686	USD -4,945	318.94 Loss of -161 on sale
2025-04-14	SELL	-15	322.320	327.850	327.297	USD -4,909	318.90 Loss of -126 on sale
2025-04-09	SELL	-20	313.950	333.320	331.383	USD -6,628	319.11 Loss of -245 on sale
2025-04-07	SELL	-35	310.520	321.590	320.483	USD -11,217	319.40 Loss of -38 on sale
2025-04-04	SELL	-50	314.390	325.080	324.011	USD -16,201	319.46 Loss of -228 on sale
2025-03-31	BUY	5	331.230	333.000	332.823	USD 1,664	319.08
2025-03-19	SELL	-10	340.770	341.180	341.139	USD -3,411	317.00 Loss of -241 on sale
2025-03-14	SELL	-30	348.350	348.350	348.350	USD -10,451	315.90 Loss of -974 on sale
2025-03-13	SELL	-10	323.020	332.400	331.462	USD -3,315	315.80 Loss of -157 on sale
2025-03-12	SELL	-170	327.310	344.170	342.484	USD -58,222	315.63 Loss of -4,565 on sale
2025-03-07	SELL	-10	331.410	339.080	338.313	USD -3,383	314.89 Loss of -234 on sale
2025-03-06	SELL	-15	328.770	350.000	347.877	USD -5,218	314.67 Loss of -498 on sale
2025-03-03	SELL	-5	313.470	335.400	333.207	USD -1,666	314.06 Loss of -96 on sale
2025-02-28	BUY	337	341.270	342.270	342.170	USD 115,311	313.61
2025-02-26	SELL	-4	355.880	377.460	375.302	USD -1,501	312.52 Loss of -251 on sale
2025-02-25	SELL	-12	309.490	320.540	319.435	USD -3,833	312.57 Loss of -82 on sale
2025-02-18	BUY	20	339.870	341.020	340.905	USD 6,818	310.12
2025-02-13	BUY	4	351.710	352.990	352.862	USD 1,411	308.21
2025-02-12	BUY	4	340.170	340.180	340.179	USD 1,361	307.55
2025-02-11	BUY	12	331.790	336.710	336.218	USD 4,035	307.05
2025-02-06	BUY	36	330.270	349.280	347.379	USD 12,506	305.28
2025-01-27	BUY	4	310.920	314.590	314.223	USD 1,257	300.31
2024-12-30	BUY	20	311.620	315.270	314.905	USD 6,298	297.51
2024-12-06	BUY	16	320.840	321.990	321.875	USD 5,150	295.53
2024-12-05	BUY	4	313.050	321.140	320.331	USD 1,281	294.93
2024-12-04	BUY	20	318.480	328.170	327.201	USD 6,544	294.08
2024-11-29	BUY	20	328.190	331.150	330.854	USD 6,617	290.65
2024-11-27	BUY	16	331.450	336.450	335.950	USD 5,375	287.10
2024-11-26	BUY	4	336.740	347.060	346.028	USD 1,384	284.85
2024-11-21	BUY	20	329.240	329.930	329.861	USD 6,597	276.04
2024-11-20	BUY	12	317.090	323.990	323.300	USD 3,880	273.76
2024-11-18	BUY	48	303.490	308.430	307.936	USD 14,781	269.37
2024-11-12	BUY	32	339.040	341.190	340.975	USD 10,911	264.73
2024-11-08	BUY	20	350.700	357.050	356.415	USD 7,128	258.59
2024-11-07	BUY	60	354.850	368.290	366.946	USD 22,017	251.19
2024-11-06	BUY	8	338.220	345.040	344.358	USD 2,755	243.93
2024-10-31	BUY	4	259.340	263.540	263.120	USD 1,052	209.92

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MDGL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	47,045	0	91,140	51.6%
2025-09-18	97,595	20	142,264	68.6%
2025-09-17	42,376	0	98,931	42.8%
2025-09-16	36,679	0	65,323	56.2%
2025-09-15	48,309	1,382	89,383	54.0%
2025-09-12	27,868	0	66,491	41.9%
2025-09-11	35,091	8	87,948	39.9%
2025-09-10	42,485	0	107,394	39.6%
2025-09-09	47,597	6	138,647	34.3%
2025-09-08	283,857	3,995	334,494	84.9%
2025-09-05	49,783	2,100	120,358	41.4%
2025-09-04	42,495	1,235	92,061	46.2%
2025-09-03	75,350	249	148,253	50.8%
2025-09-02	101,513	0	187,524	54.1%
2025-08-29	52,376	100	114,355	45.8%
2025-08-28	54,862	800	124,336	44.1%
2025-08-27	78,576	0	148,945	52.8%
2025-08-26	57,904	0	124,869	46.4%
2025-08-25	50,370	103	95,261	52.9%
2025-08-22	110,879	1,848	187,031	59.3%
2025-08-21	130,924	2,837	216,683	60.4%
2025-08-20	70,090	2,873	137,727	50.9%
2025-08-19	119,364	0	209,091	57.1%
2025-08-18	237,903	1,300	399,192	59.6%
2025-08-15	49,094	2,882	80,973	60.6%
2025-08-14	77,462	29	130,476	59.4%
2025-08-13	145,247	3,549	248,832	58.4%
2025-08-12	98,720	1,400	172,448	57.2%
2025-08-11	56,819	0	103,426	54.9%
2025-08-08	108,189	1,125	175,931	61.5%
2025-08-07	99,632	100	161,147	61.8%
2025-08-06	72,448	1	114,644	63.2%
2025-08-05	363,796	372	508,273	71.6%
2025-08-04	113,595	28	143,880	79.0%
2025-08-01	53,528	7	83,201	64.3%
2025-07-31	157,774	14	224,329	70.3%
2025-07-30	146,348	1	206,638	70.8%
2025-07-29	78,601	169	118,742	66.2%
2025-07-28	69,568	789	106,078	65.6%
2025-07-25	53,062	84	106,597	49.8%
2025-07-24	60,939	71	105,410	57.8%
2025-07-23	62,210	2	148,706	41.8%
2025-07-22	131,037	243	192,027	68.2%
2025-07-21	26,502	13	43,688	60.7%
2025-07-18	94,965	459	136,919	69.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE